Potential synergism of abemaciclib with chloroquine and disulfiram/copper in atypical meningioma: A case report and review of the literature

Effective salvage therapy for atypical and anaplastic meningiomas has not been established.Phase I/II clinical trial evidence for using cyclin-dependent kinase (CDK) inhibitors to treat meningiomas, in particular abemaciclib, has been documented.We aim to report a case to demonstrate the possible utility of a multitargeted treatment approach in aggressive meningiomas.We present a 38-year-old woman with progressive multifocal Grade 2 atypical meningiomas expressing clinical and radiologic response to a multidrug regimen centered on abemaciclib based on genetic profiling.Mechanistically, combining abemaciclib with drugs that antagonize potential resistance mechanisms induced by CDK inhibitors, may synergistically promote cytotoxic effects in meningiomas.This case highlights the combination of abemaciclib with chloroquine and disulfiram/copper as a prospective novel salvage therapy for recurrent atypical meningiomas.